A prospectively randomized trial was undertaken to compare dacarbazine (DTIC) alone with
DTIC plus interferon in patients with metastatic malignant melanoma. Of the 73 patients who …

Sixty-four patients with histologically confirmed metastatic malignant melanoma were
entered on a prospectively controlled randomized trial. Patients received dacarbazine …

Following extensive phase II trials of the combination of dacarbazine and interferon-alpha
2a we performed a prospective, randomized, controlled trial of this combination versus …

52 patients with metastatic melanoma have been treated with a combination of recombinant
interferon-alfa-2b, dacarbazine and nimustine. The objective response rate was 23% with 9 …

PURPOSE Some phase II studies have suggested that the combination of interferons (IFNs)
with dacarbazine (DTIC) in the treatment of malignant melanoma (MM) increases the …

Based on the report of some activity of combination therapy with dacarbazine (DTIC) and
interferon [alpha]-2a (rIFN [alpha]-2a) in disseminated melanoma, we conducted a phase II …

A phase II trial was conducted to determine the efficacy and toxicity of the addition of
interferon-[alpha] 2b (IFN-a [alpha]) to the chemotherapy combination of dacarbazine …

In May 1989, at the convention of the American Society of Clinical Oncology, a resurgence of
interest in combinations of interferon (IFN) with dacarbazine (DTIC) for therapy of metastatic …

The purpose of this study was to compare the response rate, overall and 1-year survival in
patients with advanced melanoma treated with a standard therapy, dacarbazine and …

PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival,
and toxicity in patients with metastatic melanoma treated with dacarbazine alone …